PEANUT ALLERGY

This phase 2 study tested the drug Xolair (omalizumab) in 11 people with peanut allergies who had already completed a previous trial. The goal was to see if the drug could reduce serious allergic reactions. Participants received regular injections of Xolair and reported any peanu…

This study tested whether adding the drugs omalizumab (Xolair) or dupilumab (Dupixent) to oral immunotherapy (OIT) helps people with multiple food allergies tolerate more allergens. 130 participants aged 4 to 55 with allergies to peanut plus one or two other foods were enrolled. …

This study tested a daily tablet placed under the tongue (SLIT) containing peanut protein to help people with peanut allergy tolerate small amounts of peanut. The trial included 209 adults, teens, and children ages 4 to 65. Researchers measured how many participants could safely …

This early-stage trial tested whether taking fecal transplants in capsules could help people with peanut allergy tolerate more peanut without a reaction. Fifteen adults aged 18 to 40 received the treatment, and researchers checked for side effects and changes in peanut tolerance.…

This small pilot study tested whether adding a prebiotic fiber (a type of plant fiber found in grocery stores) to peanut oral immunotherapy could help children aged 4 to 17 with peanut allergy tolerate more peanut protein with fewer side effects. Twenty children participated, and…

This study tested whether giving children with peanut allergy a daily dose of peanut protein (either 150 mg or 300 mg) could help them tolerate more peanuts over time. 44 children participated, and researchers measured how much peanut protein they could safely eat after treatment…

This early-stage trial tested a single injection of a new drug called IGNX001 in 32 adults and teens with peanut allergies. The main goal was to check safety and how the body processes the drug. Participants received either the drug or a placebo, and researchers monitored for sid…

This study tested whether omalizumab (Xolair), an allergy drug, helps people with peanut and at least two other food allergies eat those foods without severe reactions. Over 470 participants aged 1 to 55 received omalizumab or a placebo, and some also got oral immunotherapy. The …

This completed study looked at 147 French children with confirmed peanut or tree nut allergies to see how often they accidentally have allergic reactions in everyday life. Researchers also recorded how severe those reactions were and what factors might increase risk. The goal is …